Menu Search
Equities

Promimic AB

B0T:DUS

Promimic AB

Actions
  • Price (EUR)2.76
  • Today's Change-0.02 / -0.72%
  • Shares traded5.00
  • 1 Year change--
  • Beta--
Data delayed at least 15 minutes, as of May 31 2024 18:31 BST.
More ▼
Improved Notifications for Markets Data Alerts
Improved Notifications for Markets Data Alerts
Want push notifications sent directly to your devices for equity price changes and breaking news stories? Let us know here.
 
Existing alertsView our existing alerts
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Promimic AB is a Sweden-based biomaterial company. The Company manufactures, markets and sells biomaterials for improved osseointegration (bone healing) to the companies in the markets for orthopedic and dental implants. The Company operates primarily in the United States, Europe, and South America, with current product applications in the dental, spine, total joint, extremities, and sports medicine implant markets.

  • Revenue in SEK (TTM)39.53m
  • Net income in SEK-9.38m
  • Incorporated2004
  • Employees17.00
  • Location
    Promimic ABc/o AstraZeneca R&D MolndalMOELNDAL 431 83SwedenSWE
  • Phone+46 31160860
  • Websitehttps://promimic.com/
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.